Intellia Therapeutics Inc. (NTLA)
The 3 Best Cathie Wood Stocks to Buy in August 2024
As a rule of thumb, you want to make market decisions based on a wide range of assessments and not just on the recommendation of a popular investor. That said, if you had to trade with a particular individual, you can do a lot worse than so-called Cathie Wood stocks.
Intellia Therapeutics Is Expanding The Scope Of Gene Editing (Technical Analysis)
The future is here
All You Need to Know About Intellia Therapeutics (NTLA) Rating Upgrade to Strong Buy
Intellia Therapeutics (NTLA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The Bull Case for Intellia Therapeutics Stock Just Got Even Stronger
Intellia Therapeutics makes gene editing therapies. Some of those therapies could theoretically cure certain patients.
3 Pharma Stocks Already Ushering in the Next Biotech Boom
Let's get down to it: why should investors consider pharma stocks? Primarily, it comes down to the permanence of the underlying narrative.
Intellia (NTLA) Shares Fall as CFO Glenn Goddard Steps Down
Intellia (NTLA) appoints Edward Dulac as its new chief financial officer after Glenn Goddard steps down from his role with effect from Jun 30.
Intellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry
Intellia's (NTLA) lead genome-editing candidate, NTLA-2001 being developed to treat transthyretin (ATTR) amyloidosis, holds promise. Other pipeline candidates are also progressing well.
These 2 Words Are Why Intellia Therapeutics Could Be a Smart Buy Right Now
Intellia Therapeutics has a gene editing therapy that looks to be quite effective. That's favorable for the program's chances of getting approved.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Wood added to her positions in Reddit, Intellia Therapeutics, and PagerDuty on Wednesday. Wood's Ark Invest was a buyer of Reddit the day it went public in March.
Intellia Therapeutics Presents Promising In Vivo CRISPR Results
Intellia Therapeutics has released positive data from its Phase I/II study of NTLA-2002, a CRISPR-based gene editing therapy. The study shows promising results for in vivo gene editing, offering potential treatments for genetic diseases. Robust target engagement and efficacy data pave the way for future Phase II results from Intellia later this year.
Intellia (NTLA) Up on Upbeat Long-Term Angioedema Study Data
Intellia (NTLA) gains 10% after reporting encouraging long-term efficacy data from the phase I portion of its early to mid-stage study evaluating NTLA-2002 for treating hereditary angioedema.
